<DOC>
	<DOC>NCT00106301</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable disease on prior Fujisawa sponsored FK228 clinical trials.</brief_summary>
	<brief_title>Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228</brief_title>
	<detailed_description>This is a Phase II, non-randomized, open-label, single arm, continuation trial.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Patient has completed 6 cycles of therapy in a prior Fujisawasponsored FK228 clinical trial; Patient has immediate past participation (not to exceed 21 days from Day 15 of cycle 6 in the previous study) in a prior Fujisawasponsored FK228 clinical trial; Patient has demonstrated stable disease, partial response or complete response as best overall response in their prior Fujisawasponsored FK228 clinical trial. Patient has been on a prior Fujisawasponsored FK228 clinical trial, left the trial and then received alternative antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>FK228</keyword>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
</DOC>